Cross-ancestry Study Identifies Novel Obesity Genes and Explains Global Risk Variations
Bridging Genetic Diversity in Obesity Research
Obesity remains a global public health challenge, driving conditions such as heart disease, Type 2 diabetes, and osteoarthritis. While lifestyle factors like diet and activity are crucial, genetic factors also play a major role in an individual’s susceptibility. Until now, most obesity genetics research has focused heavily on European populations, limiting global understanding of obesity risk.
Researchers at Penn State conducted a massive cross-ancestry genetic study involving 839,110 adults across six continental ancestries — African, American, East Asian, European, Middle Eastern, and South Asian. Their rare-variant association analysis of body mass index (BMI) uncovered new insights into the shared and unique genetic factors influencing it.
Explore All Endocrinology CME/CE Conferences and Online Courses
New Genes, Global Insight, and Clinical Relevance
The team identified 13 genes linked to risk across populations. Of these, five were novel discoveries — YLPM1, RIF1, GIGYF1, SLC5A3, and GRM7 — while others, such as MC4R and BSN, had been recognized in previous studies. Notably, YLPM1 showed consistent associations with obesity across ancestries, revealing its global clinical relevance.
The study also examined how these genes interact with comorbidities, including Type 2 diabetes, hypertension, and heart failure. Using mediation analysis, the researchers demonstrated that certain genes, such as GIGYF1 and SLTM, increased diabetes risk both directly and indirectly through elevated BMI.
For healthcare professionals, this offers an improved understanding of how genetic variants influence both obesity and its downstream complications — a vital step toward precision medicine approaches that consider ancestry diversity.
What the Findings Mean for Healthcare Professionals
These results emphasize that obesity risk is shaped by a combination of rare and common genetic variants acting together. The presence of diverse populations in this study corrects historical biases in genomic research, improving its global applicability.
For clinicians, the findings could inform personalized care strategies by identifying genetic markers that indicate higher susceptibility to it and related diseases. Additionally, several identified genes correspond to changes in plasma proteins, such as LECT2 and NCAN, which may serve as future biomarkers or therapeutic targets.
By expanding genetic databases and ensuring inclusive research, healthcare professionals can better assess risk, guide prevention, and develop ancestry-informed treatment strategies.
The Path Forward for HCPs and Researchers
- Incorporate awareness of ancestry-specific genetic findings in obesity assessment.
- Support inclusion of underrepresented groups in genetic studies.
- Track emerging biomarkers linked to obesity-related genes for early diagnosis.
- Educate patients about the interplay of genetics, ancestry, and lifestyle in obesity risk.
This cross-ancestry study highlights the importance of global representation in medical research, ensuring that future obesity treatments and prevention strategies are equitable, effective, and clinically relevant worldwide.
Source:
more recommended stories
England Obesity Prevalence Climbs to 30%, Lancet StudyKey Points A nationwide study of.
Rheumatoid Arthritis Linked to SPP1hi Macrophages GrowthKey Summary Researchers at Hospital for.
Resistance Training Reduces Type 2 Diabetes Risk in AdultsKey Takeaways Consistent resistance training was.
Cardiac Aging Research Identifies PRDM16 Heart RegulatorKey Takeaways Researchers created a single-nucleus.
Digital Heart Twins Show Promise for AF Ablation PrecisionKey Summary Researchers developed patient-specific digital.
Alzheimer’s Disease Study Questions Glucosamine SafetyKey Summary New research published in.
Women’s Healthcare Advances Through FemTechKey Summary FemTech has grown from.
WHO: Andes Hantavirus Not a COVID-19-Level ThreatKey Summary Andes hantavirus has drawn.
Mazdutide Shows Significant Weight Loss in Phase 3 TrialKey Summary Mazdutide, a dual GLP-1.
Genetic Screening Project Launches for Brazilian ParentsKey Summary Brazil is launching the.

Leave a Comment